Glaxo to Begin Hostile Offer for Human Genome Sciences

GlaxoSmithKline Plc will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S. company, its partner on the Benlysta drug for lupus, rebuffed a takeover approach.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.